RESUMO
Chemical reaction interface mass spectrometry (CRIMS) was coupled on-line with HPLC using a Vestec particle beam interface. A helium-assisted nebulizer provided added stability with no loss in accuracy or precision as compared to the thermospray nebulizer at flow rates of up to 1.0 mL/min using isocratic conditions. However, mass spectral response was found to be solvent-dependent for both the helium-assisted and thermospray nebulizers. Postcolumn solvent addition of methanol eliminated solvent-dependent decreases in mass spectral response. This allowed gradient HPLC elutions to be performed. Under these conditions, the flow of solvent into the particle beam interface was 2.5 mL/min, so a conventional thermospray nebulizer had to be used instead of the helium-assisted nebulizer. Experiments were conducted with the antianxiety agent buspirone in order to validate the methodology. Metabolites from in vitro incubations of [15N]/[14C]buspirone with rat liver slices were analyzed by gradient LC/CRIMS and by gradient LC/[14C] radioactivity counting. The response from LC/CRIMS analysis for individual metabolites was then compared with that obtained by LC/[14C] radioactivity counting. An excellent correlation was observed between the two methods for metabolites with quite different HPLC characteristics. Thus, gradient LC/CRIMS in combination with stable isotopes provides an alternative to using radioisotopes for carrying out drug metabolism studies.
Assuntos
Preparações Farmacêuticas/metabolismo , Animais , Buspirona/análise , Buspirona/metabolismo , Buspirona/farmacocinética , Cromatografia Líquida de Alta Pressão , Técnicas In Vitro , Espectrometria de Massas , Preparações Farmacêuticas/análise , Ratos , Agonistas do Receptor de Serotonina/análise , Agonistas do Receptor de Serotonina/metabolismo , Agonistas do Receptor de Serotonina/farmacocinética , Solventes , Espectrofotometria UltravioletaRESUMO
Safety, tolerance, and preliminary pharmacokinetics of nefazodone, a new antidepressant, were assessed in a randomized, double-blind, parallel group study carried out in two sequential segments: a single and a multiple daily dose segment. Nine subjects in the single daily dose segment were divided into three treatment groups and received nefazodone doses in a leapfrog fashion. Each day of treatment with nefazodone was followed by 2 days of placebo treatment and then administration of the next higher drug dose. Single doses ranged from 5-500 mg. 8 subjects enrolled in the multiple daily dose segment were divided into two treatment groups. In each group, 3 subjects received nefazodone and one received placebo 3 times a day. Each dosage level was administered for 2 days before proceeding to the next higher dose from 5 mg or 10 mg 3 times a day to a maximum of 500 mg 3 times a day. After the dose-escalation period, the subjects in the multiple daily dose segment underwent a 3-day washout, after which they received a single dose of nefazodone at the maximum tolerated level. Safety and tolerance assessment involved analyses of adverse events, laboratory tests, vital signs, ophthalmic examinations, and ECGs. Blood and urine samples were obtained only in the multiple daily dose segment and analyzed for nefazodone and its two pharmacologically active metabolites, hydroxynefazodone and mCPP. A single blood sample was collected on 8 different days for assessment of trough levels (Cmin) and serial samples were obtained on days 5, 9, and 22 of dosing for pharmacokinetic profiles. Additional serial samples were also obtained after the last single dose of 500 mg after a 3-day washout. Nefazodone was found to be safe and well-tolerated in total daily doses as high as 1350 mg (450 mg 3 times a day). Nefazodone was rapidly absorbed after oral administration and converted to hydroxynefazodone and mCPP. The pharmacokinetics of nefazodone, hydroxynefazodone, and mCPP were found to be dose-dependent, as evidenced by dose normalized values of Cmin, Cmax, and AUC0-8 that progressively increased with dose. Although exposure of normal subjects to nefazodone and its 2 pharmacologically active metabolites was disproportionately higher than the corresponding increase in dose, the safety and tolerance profiles did not show a parallel increase in adverse events. Nefazodone may be well-tolerated by patients receiving expected therapeutic doses from 200-600 mg per day when administered in divided doses every 8 to 12 hours.
Assuntos
Antidepressivos de Segunda Geração/farmacocinética , Triazóis/farmacocinética , Administração Oral , Adulto , Antidepressivos de Segunda Geração/administração & dosagem , Antidepressivos de Segunda Geração/farmacologia , Método Duplo-Cego , Esquema de Medicação , Tolerância a Medicamentos , Humanos , Masculino , Pessoa de Meia-Idade , Piperazinas/farmacocinética , Triazóis/administração & dosagem , Triazóis/farmacologiaRESUMO
Metabolism of the antidepressant drug nefazodone was studied in humans after single and multiple 50 and 200 mg oral doses of [14C] nefazodone as part of a single and multiple dose balance study. Deuterium was included in the molecule to facilitate structural characterization of the metabolites by mass spectrometry. Metabolites were isolated from a 0-24 hr pooled urine from three subjects and purified to homogeneity by HPLC. Chemical structures of the metabolites were proposed based on collisionally induced dissociation (CID) and electron impact ionization MS. The profile of radioactivity showed three main urinary metabolites, one of which was a conjugate, and several minor metabolites. The three major metabolites were identified as the phenoxyethyl triazolone propionic acid resulting from N-dealkylation of both nefazodone and hydroxynefazodone (OH-Nef), as well as a corresponding phenoxyethyl triazolone propanol metabolite of N-dealkylated nefazodone, present exclusively as a conjugate. The more polar minor components were not identified. The excretion of total radioactivity in the 24-hr sample was 49% of the dose, of which the identified metabolites comprised 38% of the dose. There was no difference in the qualitative or quantitative urinary profile of the metabolites at 50 or 200 mg dose levels after single or multiple oral dosing. These N-dealkylated metabolites were also present in pooled human plasma samples along with nefazodone, OH-Nef, and an unknown metabolite that was present in plasma in large amounts relative to nefazodone and OH-Nef. This metabolite was isolated from plasma and from a human liver S9 incubation and identified by CID tandem MS and NMR as the triazoledione of nefazodone.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Antidepressivos/farmacocinética , Triazóis/farmacocinética , Animais , Antidepressivos/sangue , Antidepressivos/urina , Biotransformação , Cromatografia Líquida de Alta Pressão , Remoção de Radical Alquila , Cães , Humanos , Técnicas In Vitro , Fígado/metabolismo , Espectroscopia de Ressonância Magnética , Masculino , Espectrometria de Massas , Piperazinas , Espectrofotometria Infravermelho , Espectrofotometria Ultravioleta , Triazóis/sangue , Triazóis/urinaAssuntos
Piperazinas/farmacocinética , Piperazinas/urina , Animais , Masculino , Oxirredução , Piperazinas/química , Ratos , Ratos Sprague-DawleyRESUMO
A series of three-way crossover randomized studies were conducted to evaluate the absolute bioavailability of butorphanol, a potent agonist-antagonist analgesic, from transnasal, sublingual, and buccal disk formulations in order to identify a practical alternative to oral administration. In each study, healthy male volunteers received 2 mg doses of butorphanol tartrate intravenously and either transnasally, sublingually or buccally. Serial blood samples were collected over 12 h and butorphanol plasma concentrations were determined by radioimmunoassay. The plasma concentration data were subjected to non-compartmental pharmacokinetic analysis. The elimination half-life of butorphanol was about 3-5 h and was independent of the route of administration. Absorption of butorphanol following transnasal administration was faster than that observed following sublingual or buccal administration. Mean absolute bioavailabilities of sublingual tablet and buccal disk formulation were only 19 per cent and 29 per cent, respectively, but for transnasal administration the value rose significantly, to 70 per cent. Based on the results of these studies, transnasal dosage form of butorphanol was selected for further clinical trials of treatment of moderate to severe pain.
Assuntos
Butorfanol/administração & dosagem , Butorfanol/farmacocinética , Administração Bucal , Administração Intranasal , Administração Sublingual , Adolescente , Adulto , Disponibilidade Biológica , Butorfanol/sangue , Humanos , Masculino , RadioimunoensaioRESUMO
Metabolism of the antipsychotic drug tiospirone was studied in humans after a single 60-mg oral dose of [14C]tiospirone. Metabolites were isolated from a 0-24 hr pooled urine from eight subjects, which represented 39% of the dose, and purified to homogeneity by HPLC. Purified metabolites were identified by desorption chemical ionization mass spectrometry in the positive ion mode with methane as a reagent gas. Structures of the metabolites were confirmed by coelution on HPLC in several systems with synthetic standards. In addition to unchanged tiospirone, five metabolites of tiospirone were identified and one additional metabolite was partially identified. Based on the structures of these metabolites, five routes of metabolism of tiospirone were identified: N-dealkylation of the butyl side chain attached to the piperazinyl nitrogen, hydroxylation alpha to the glutarimidyl carbonyl at the 6'-position on the spiro ring, hydroxylation at the 3'-position on the spiro ring, oxidation at sulfur resulting in the formation of sulfones, and oxidation at carbon alpha to the piperazinyl nitrogen resulting in the formation of a lactam-sulfone. The major urinary metabolites were benzisothiazole piperazine sulfone and its lactam derivative, accounting for 5.0 and 4.3% of the dose, respectively. The identified metabolites accounted for 50% of the total radioactivity in the urine (approximately 20% of the dose). The remaining radioactive components were extremely heterogeneous and could not be isolated in sufficient quantities to characterize. A scheme for the metabolism of tiospirone in humans is proposed.
Assuntos
Psicotrópicos/metabolismo , Compostos de Espiro/metabolismo , Biotransformação , Cromatografia Líquida de Alta Pressão , Humanos , Masculino , Espectrometria de Massas , Compostos de Espiro/urinaRESUMO
1. Metabolism of the antianxiety drug buspirone was studied by in vitro incubations with rat liver microsomes and hepatocytes. Metabolites were isolated and purified by h.p.l.c. The purified metabolites were identified by co-elution on h.p.l.c. with authentic standards and by g.l.c.-electron impact mass spectrometry of their trimethylsilyl (TMS) derivatives. 2. Five metabolites of buspirone were identified in the microsomal incubates and seven in the hepatocyte incubates. The major metabolites arose from aromatic hydroxylation at C-5, N-dealkylation of the butyl chain, and hydroxylation at C-6' and C-3' on the azaspirodecanedione moiety. 3. Metabolism of buspirone by rat liver microsomes was NADPH-dependent and was completely inhibited by cytochrome P-450 inhibitors SKF-525A and metyrapone. 4. Metabolites of buspirone formed in vitro were good predictors of the primary metabolites formed in vivo. 5. Hepatocytes and phenobarbital-induced rat liver microsomes were better predictors of in vivo metabolism of buspirone than non-induced rat liver microsomes. These in vitro systems should provide excellent models for studying the metabolism of other azaspirodecanedione-containing drugs.
Assuntos
Buspirona/metabolismo , Fígado/metabolismo , Microssomos Hepáticos/metabolismo , Animais , Cromatografia Líquida de Alta Pressão , Inibidores das Enzimas do Citocromo P-450 , Cromatografia Gasosa-Espectrometria de Massas , Hidroxilação , Masculino , Metirapona/farmacologia , Microssomos Hepáticos/efeitos dos fármacos , NADP/farmacologia , Fenobarbital/farmacologia , Piridinas/farmacologia , Ratos , Ratos EndogâmicosRESUMO
Metabolism of the antipsychotic drug tiospirone was studied in vitro with phenobarbital-induced rat liver microsomes. Metabolites were isolated and purified to homogeneity by high-performance liquid chromatography. It was possible to characterize the metabolites as trimethylsilyl (TMS) derivatives by gas chromatography/electron impact mass specrometry (GC/EIMS) so long as the sulfur was present in the reduced form. However, sulfoxide and sulfone analogs of tiospirone underwent reductive decomposition on the GC column. In addition, no molecular ions were observed in the EI spectra of these analogs. Desorption chemical ionization/mass spectrometry (DCI/MS) in the positive ion mode with methane as reagent gas successfully distinguished sulfoxides and sulfones from their parent sulfides. Protonated molecular ions were observed together with structurally significant fragment ions. Five microsomal metabolites of tiospirone were characterized by a combination of GC/EIMS and DCI/MS. From the structures of the metabolites three major pathways of metabolism were identified: N-dealkylation of the butyl side chain at the piperazinyl nitrogen, hydroxylation alpha to the glutarimidyl carbonyl at C-6 on the azaspirodecanedione ring, and sulfoxide formation on the benzisothiazole moiety.
Assuntos
Psicotrópicos/metabolismo , Compostos de Espiro/metabolismo , Animais , Cromatografia Líquida de Alta Pressão , Cromatografia Gasosa-Espectrometria de Massas , Técnicas In Vitro , Masculino , Microssomos Hepáticos/metabolismo , Ratos , Ratos EndogâmicosRESUMO
Metabolism of the antiarrhythmic drug encainide was studied in human subjects after a single 50-mg oral dose. Encainide labeled on the carbonyl carbon with 14C and at the benzylic (2'-1-ethyl) carbon with 13C was administered to four normal healthy male subjects. A large proportion of the radioactive dose (42%) was excreted in the urine in the first 24 hr. The total urinary excretion was 47.0 +/- 4.6% and total fecal excretion was 38.7 +/- 5.7% over 5 days. The conjugated metabolites excreted in the urine were hydrolyzed with beta-glucuronidase/arylsulfatase, and were isolated and purified by HPLC. Structural characterization was carried out by a combination of fast atom bombardment-mass spectrometry, gas chromatography/electron impact mass spectrometry, and 1H-NMR spectroscopy. Structures of the metabolites were confirmed by co-elution on HPLC with authentic standards when available. Six metabolites of encainide were identified from the hydrolyzed urine together with unchanged drug. In addition to already known metabolites O-demethyl-encainide, 3-methoxy-O-demethyl-encainide, and N,O-di-demethyl-encainide, three new metabolites were identified: N-demethyl-3-methoxy-O-demethyl-encainide, 3-hydroxy-encainide, and O-demethyl-encainide-lactam. These metabolites accounted for greater than 90% of the radioactivity excreted in the urine. Four major routes of metabolism were identified: first, O-demethylation of the aromatic methyl ether; second, formation of methylated catechol derivatives; third, N-demethylation of the piperidyl nitrogen; and fourth, oxidation at carbon alpha to the piperidyl nitrogen. A plausible scheme for the metabolism of encainide in human subjects is proposed.
Assuntos
Anilidas/urina , Arilsulfatases/metabolismo , Biotransformação , Cromatografia Líquida de Alta Pressão , Encainida , Cromatografia Gasosa-Espectrometria de Massas , Glucuronidase/metabolismo , Humanos , Hidrólise , Espectroscopia de Ressonância Magnética , Masculino , Espectrometria de Massas , Peso Molecular , Espectrofotometria UltravioletaRESUMO
The metabolism of an orally administered, 10-mg single dose of the antianxiety drug buspirone was studied in the rat. Samples of bile and urine were collected for 6 hr and were treated with beta-glucuronidase/arylsulfatase. The deconjugated metabolites were isolated and purified by HPLC. Structural analysis was carried out by combined gas chromatography/electron impact mass spectrometry as their trimethylsilyl derivatives and by 1H-NMR spectroscopy. Structures of the metabolites were further confirmed by co-elution on HPLC with authentic standards when possible. In addition to the already known metabolites 5-hydroxy-buspirone and 1-pyrimidinylpiperazine, seven major metabolites were unambiguously identified together with unchanged drug. Ten minor metabolites were partially characterized. Hydroxylation alpha to the glutaramidyl carbon at the 6'-position on the bicyclo ring system, hydroxylation on the pyrimidine aromatic ring, and N-dealkylation of the butyl side chain were observed as major routes of metabolism. Minor routes of metabolism observed were: 3'-hydroxylation on the bicyclo ring system and formation of the methylated catechol derivatives. The identified metabolites accounted for greater than 90% of the total metabolites excreted in the rat bile and urine samples.
Assuntos
Buspirona/metabolismo , Animais , Bile/metabolismo , Biotransformação , Buspirona/urina , Cromatografia Líquida de Alta Pressão , Cromatografia Gasosa-Espectrometria de Massas , Hidrólise , Espectroscopia de Ressonância Magnética , Masculino , Ratos , Ratos EndogâmicosRESUMO
The metabolism of an oral dose (20 mg) of the antianxiety drug buspirone labeled with 14C/15N was studied in human subjects. 15N was incorporated in the molecule to facilitate structural characterization of the metabolites by mass spectrometry. Urine samples were collected at intervals up to 24 hr and analyzed for radioactivity. Cumulative urinary excretion accounted for 50% of the dose in 24 hr. The urine was hydrolyzed with beta-glucuronidase/arylsulfatase and the deconjugated metabolites were isolated and purified by HPLC. The purified metabolites were identified by GC/MS, 1H-NMR, and comparison with authentic standards when available. Seven metabolites of buspirone were identified unambiguously, together with unchanged drug. Hydroxylation alpha to the glutarimidyl carbonyl at the 6'-position on the spiro ring system, hydroxylation at the 5-position on the pyrimidine ring, and N-dealkylation of the butyl-substituted side chain were major routes of metabolism. The identified metabolites accounted for 88% of the total radioactivity in the urine. A scheme for metabolism of buspirone in human subjects has been proposed.
Assuntos
Buspirona/metabolismo , Biotransformação , Buspirona/urina , Cromatografia Líquida de Alta Pressão , Fezes/análise , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Espectroscopia de Ressonância Magnética , Espectrometria de MassasRESUMO
Commercially available chiral columns were unable to provide adequate resolution of enantiomers of the antiarrhythmic drug encainide or its major metabolites. The homochiral derivatizing agent, (-)-menthyl chloroformate, was found to react at the tertiary piperidine nitrogen of racemic encainide providing two menthyl carbamate diastereomers. The individual diastereomers could be separated with baseline resolution on normal-phase high-performance liquid chromatography on a silica column. Structures of the derivatives were confirmed by electron impact mass spectrometry and 1H NMR spectroscopy. The method was adapted for the chiral analysis of the major metabolites of encainide. The limit of sensitivity for racemic encainide was 10 ng on column and it was possible to detect a mixture containing (+)- and (-)-encainide in a ratio of 1:99. Preliminary studies indicated that (-)-encainide was O-demethylated to a greater extent than the (+)-enantiomer by rat liver microsomes.
Assuntos
Antiarrítmicos/análise , Anilidas/metabolismo , Animais , Antiarrítmicos/metabolismo , Fenômenos Químicos , Química , Cromatografia Líquida de Alta Pressão , Encainida , Masculino , Espectrometria de Massas , Microssomos Hepáticos/metabolismo , Ratos , Ratos Endogâmicos , Espectrofotometria Ultravioleta , EstereoisomerismoRESUMO
Twenty-four men and 24 women ages 20-77 years received a single 15 mg oral dose of buspirone followed by 4 days of 15 mg tid administration. Plasma concentrations of buspirone and 1-pyrimidinylpiperazine following both single and multiple dosing were determined by RIA and GCMS, respectively. There were no significant differences between the young and elderly of either gender with regard to buspirone AUC, Cmax, Tmax and half-life values. The 1-PP AUC values were higher for young of either gender compared to the corresponding group of elderly subjects and the 1-PP Cmax values were higher for women than men. These differences are unlikely to be of clinical significance. The buspirone and 1-PP AUC values for a dosing interval during multiple dosing are not significantly different than the respective single dose AUC values. Buspirone treatment was well-tolerated by all subjects even though the 45 mg/day dose was 3 times the recommended starting dose in clinical practice. Overall, the lack of marked or consistent differences in buspirone or 1-PP pharmacokinetics in elderly subjects compared to younger subjects of the same gender suggest there is no need to alter the initial dose of buspirone based solely on patient age.
Assuntos
Buspirona/farmacocinética , Adulto , Idoso , Envelhecimento/metabolismo , Buspirona/efeitos adversos , Feminino , Meia-Vida , Humanos , Masculino , Grupos RaciaisRESUMO
12 patients with mild to moderate impairment of renal function and 12 healthy subjects each received 20mg buspirone as a single dose in this acute study. Six anuric patients with chronic renal failure were given two 20mg doses of buspirone, the first 2 days before haemodialysis (between dialyses) and the second during hemodialysis (2 hours before dialysis began). The differences between the median pharmacokinetic values of buspirone for healthy subjects, patients with mild to moderate renal impairment, and anuric patients were not statistically significant. Similarly, there were no significant differences between values in mild to moderate renal failure vs healthy subjects. Some of the median pharmacokinetic values for the active buspirone metabolite 1-(2-pyrimidinyl)-piperazine (1-PP), however, differed significantly for anuric patients, compared with healthy subjects or patients with mild to moderate renal impairment. When assessed between and during haemodialysis, the anuric patients had significantly (p less than 0.05) greater pharmacokinetic median values: half-life (t 1/2) = 15.2 vs 9.8 hours; area under the concentration-time curve (AUC) = 604 vs 404 nmol/L.h; and mean residence time (MRT) = 9.28 vs 6.96 hours. No firm recommendation for specific dosage can be made based on the present data. However, it does appear that in patients with mild to moderate renal impairment, the pharmacokinetics of buspirone and its active metabolite 1-PP are similar to those in individuals with normal renal function. For anuric patients higher concentrations of the 1-PP metabolite are attained while they are not undergoing haemodialysis. A dosage reduction of 25 to 50% might be necessary when buspirone is given to anuric patients.
Assuntos
Buspirona/farmacocinética , Nefropatias/metabolismo , Falência Renal Crônica/metabolismo , Rim/metabolismo , Administração Oral , Adulto , Buspirona/análogos & derivados , Buspirona/sangue , Buspirona/metabolismo , Humanos , Cinética , Masculino , Pessoa de Meia-IdadeRESUMO
A high performance liquid chromatography (HPLC) method for the quantification of encainide (4-methoxy-2'-[2-(1-methyl-2-piperidinyl)-ethyl]benzanilide hydrochloride) in plasma and urine has been developed and validated. Encainide and two metabolites, the O-demethyl (ODE) and 3-methoxy-O-demethyl (MODE) congeners of the drug, can be quantified simultaneously in plasma and urine by this procedure. The compounds are extracted from buffered plasma (pH 8.5) using N-butyl chloride containing 5% (vol/vol) isopropyl alcohol. The compounds are then separated on a silica column using ethanol:water:methanesulfonic acid, 500/60/0.2 (vol/vol/vol) as the mobile phase and quantified by measuring their UV absorbance at 254 nm. The lower limit of detection for the analytes was 5 ng/ml in plasma and 25 ng/ml in urine. The method was linear from 5 to 5,000 ng/ml for plasma and 25 to 5,000 ng/ml for urine. The intra-assay precision of the method for encainide, ODE, and MODE in plasma and urine ranged from 2 to 8% RSD depending upon concentration. The inter-assay precision of the method was less than 6% for the three analytes per ml of plasma and urine. Absolute recovery of the analytes from plasma ranged from 82 to 92%, while recoveries from urine ranged from 83 to 99%. The analytes were shown to be stable in frozen plasma and urine for up to 52 weeks.
Assuntos
Anilidas/análise , Antiarrítmicos/análise , Anilidas/sangue , Anilidas/urina , Antiarrítmicos/sangue , Antiarrítmicos/urina , Cromatografia Líquida de Alta Pressão , Encainida , Humanos , Reprodutibilidade dos TestesRESUMO
The pharmacokinetics of a single oral dose of buspirone (20 mg) were determined in 12 patients with cirrhosis and 12 normal subjects. The mean AUC of buspirone was 55 +/- 38 s.d. ng ml-1 h in cirrhotics and 3.5 +/- 2.4 s.d. ng ml-1 h in normals. The time until maximum concentration (tmax) attained was similar in the two groups (0.6 vs 0.7 h), but mean maximum concentration Cmax was higher in patients (18.8 +/- 16.3 s.d. ng ml-1) than in normals (1.2 +/- 0.8 s.d. ng ml-1). Mean elimination half-life of buspirone was greater in cirrhotics, but this difference was marginally significant statistically (cirrhotics, 6.1 +/- 3.5 s.d. h, normals 3.2 +/- 1.5 s.d. h, P = 0.05). Eight of 12 patients and seven of 12 normal subjects had a second peak in the plasma concentrations of buspirone. In patients this occurred at 10.8 +/- 7.4 s.d. h after the dose, and its mean concentration was 3.1 +/- 6.6 ng ml-1. In normal subjects the second peak occurred at 4.3 +/- 2.1 h after the dose and its mean concentration was 0.5 +/- 0.3 ng ml-1. On the kinetic evidence buspirone should be used with caution in liver disease.
Assuntos
Buspirona/farmacocinética , Cirrose Hepática/metabolismo , Adulto , Buspirona/efeitos adversos , Galactose/metabolismo , Meia-Vida , Humanos , Cirrose Hepática Alcoólica/metabolismo , Testes de Função Hepática , Masculino , Pessoa de Meia-IdadeRESUMO
The local anesthetic, antiarrhythmic, and acute toxicologic properties of the O-demethyl (ODE), 3-methoxy-O-demethyl (MODE) and N-demethyl (NDE) analogs of encainide (E) were compared with those of parent drug in several models. In the mouse chloroform-induced fibrillation model, the order of antiarrhythmic potency was ODE greater than E greater than MODE greater than NDE. The acute LD50 values for ODE, E, MODE and NDE in mice were 22.6, 38.1, 43.6 and 81.1 mg/kg, i.p. Based upon the toxic/therapeutic ratio in mice, ODE appeared to have the greatest margin of safety and MODE the least; E and NDE were intermediate. In dogs with ouabain-induced tachyarrhythmias, the converting doses of encainide, ODE, MODE and NDE were 0.67, 0.15, 0.39 and 1.1 mg/kg, i.v., respectively. The ODE and MODE metabolites thus appear to be more potent on a mg basis, but both have shorter durations of action than the parent compound. Antiarrhythmic activity in this model was best reflected by plasma drug level (Cp) rather than dose of drug administered. Antiarrhythmic onset Cp associated with encainide (244 ng/ml), ODE (77 ng/ml), MODE (164 ng/ml) and NDE (851 ng/ml) have been identified in this anesthetized dog model. In conscious dogs previously subjected to Harris two-stage coronary artery ligation, the minimal effective doses of encainide were 0.5 mg/kg i.v. and 1 mg/kg orally. For ODE and MODE the minimal effective doses were 0.25 and 0.19 mg/kg injected i.v., respectively, and 0.5 and 0.38 mg/kg given orally. By both routes, encainide had the shortest onset, longest duration and most consistent profile of sustained antiarrhythmic effects. Antiarrhythmic activity did not correlate with local anesthetic potency of either encainide or its metabolites. The data are consistent with the hypothesis that the metabolites of encainide may contribute to and/or be responsible, at least in part, for the persistent antiarrhythmic actions observed clinically following chronic administration of the parent drug in patients.
Assuntos
Anilidas/farmacologia , Antiarrítmicos/farmacologia , Anestésicos Locais , Anilidas/metabolismo , Anilidas/toxicidade , Animais , Antiarrítmicos/metabolismo , Antiarrítmicos/toxicidade , Biotransformação , Clorofórmio/toxicidade , Cães , Encainida , Feminino , Cobaias , Dose Letal Mediana , Masculino , Camundongos , Camundongos Endogâmicos ICR , Ouabaína/toxicidade , Testes Cutâneos , Taquicardia/induzido quimicamente , Fibrilação Ventricular/induzido quimicamente , Fibrilação Ventricular/prevenção & controleRESUMO
The metabolism and disposition of buspirone have been studied in the rat, the monkey, and in more than 150 human subjects. Buspirone is well absorbed, but is subject to first-pass metabolism. The mean systemic availability is approximately 4 percent. Buspirone is eliminated primarily by oxidative metabolism, which produces several hydroxylated metabolites, including 5-hydroxy-buspirone and 1-pyrimidinylpiperazine. The latter metabolite is from 1 to 20 percent as potent as buspirone in a variety of pharmacologic tests; 5-hydroxybuspirone is essentially inactive. In humans, the systemic exposure to buspirone increases linearly in relation to the oral dose. Food increases the bioavailability of buspirone by decreasing first-pass metabolism; absorption is not markedly altered. The pharmacokinetics of buspirone were not significantly different in men and women or in individuals 21 to 40 years old compared with those over 65 years of age. Half-life values observed in healthy volunteers ranged from two to 33 hours. Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours. The half-life in women tended to be slightly longer than in men, but the difference was not significant. Hepatic cirrhosis resulted in a marked decrease in the clearance of buspirone, which correlated with serum alkaline phosphatase activity. Renal disease produced a modest decrease in buspirone clearance, which could not be correlated with an objective clinical measurement reflecting the severity of renal impairment. Buspirone was not removed by hemodialysis. Buspirone is highly protein bound (more than 95 percent), interacting with both albumin and alpha-acid glycoprotein. However, buspirone did not displace dilantin, propranolol, digoxin, or warfarin from plasma proteins. In rats, buspirone neither inhibited nor induced hepatic mixed-function oxidases. Co-administration of buspirone with amitriptyline or diazepam did not alter the disposition of these agents or their demethylated metabolites.
Assuntos
Pirimidinas/metabolismo , Absorção , Administração Oral , Adolescente , Adulto , Idoso , Envelhecimento , Amitriptilina/metabolismo , Amitriptilina/uso terapêutico , Animais , Transtornos de Ansiedade/tratamento farmacológico , Disponibilidade Biológica , Proteínas Sanguíneas/metabolismo , Buspirona , Radioisótopos de Carbono , Feminino , Alimentos , Meia-Vida , Humanos , Injeções Intravenosas , Nefropatias/metabolismo , Cinética , Cirrose Hepática/metabolismo , Masculino , Pirimidinas/uso terapêutico , Fatores SexuaisRESUMO
Dose dependency of the pharmacokinetics of buspirone, a new anxiolytic agent, was tested in 24 healthy volunteers. Each subject received 10, 20, and 40 mg doses according to a randomized, three-way crossover design with a 7-day interval between treatments. Buspirone AUC values at 10, 20, and 40 mg doses were in the ratio of 1:1.7:3.5 while Cmax values had a ratio of 1:1.9:3.7. The dose normalized (10 mg basis) AUC and Cmax values, Tmax values, and half-lives were not significantly different (p greater than 0.05) among the doses. Buspirone half-life did not change as a function of dose (mg kg-1). It was concluded that buspirone exhibits linear pharmacokinetics following doses in the therapeutic range.